SRSF2 mutations in epithelial ovarian cancer

  • Nicoloso M
  • Schiappacassi M
  • Dall’Acqua A
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Resistance to platinum chemotherapy regimens represents a major obstacle in the successful treatment of epithelial ovarian cancer (EOC) patients. Among the molecular mechanism responsible for resistance to platinum, alternative splicing, which is induced upon platinum treatment, can control apoptosis by regulating the expression of apoptotic protein variants with opposite functions. Alterations in alternative splicing are found in tumors and can hinder apoptotic response. In the present study we sequenced SRSF2, a splicing factor that regulates Caspase-8 and Caspase-9 variants, in search of mutations that could possibly explain alternative mechanisms of platinum resistant in EOC.

Cite

CITATION STYLE

APA

Nicoloso, M. S., Schiappacassi, M., Dall’Acqua, A., D’Andrea, S., Benevol, S., Sorio, R., … Baldassarre, G. (2017). SRSF2 mutations in epithelial ovarian cancer. Cancer Breaking News, 5(3), 25–29. https://doi.org/10.19156/cbn.2017.0056

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free